MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults

By / 11/09/2023

MBX Biosciences, Inc. today announced positive results from the multiple ascending dose (MAD) portion of the Phase 1 trial of MBX 2109.